These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17360107)

  • 1. Editorial comment on: effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
    Gratzke C
    Eur Urol; 2007 Sep; 52(3):848. PubMed ID: 17360107
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment on: effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
    Reitz A
    Eur Urol; 2007 Sep; 52(3):848-9. PubMed ID: 17360105
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
    Iijima K; De Wachter S; Wyndaele JJ
    Eur Urol; 2007 Sep; 52(3):842-7. PubMed ID: 17360104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice.
    Yamada S; Maruyama S; Takagi Y; Uchida S; Oki T
    Life Sci; 2006 Dec; 80(2):127-32. PubMed ID: 16996089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.
    Hill S; Khullar V; Wyndaele JJ; Lheritier K;
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 May; 17(3):239-47. PubMed ID: 15999217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers.
    Kay GG; Wesnes KA
    BJU Int; 2005 Nov; 96(7):1055-62. PubMed ID: 16225528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function.
    Golding JF; Wesnes KA; Leaker BR
    Br J Clin Pharmacol; 2018 Jul; 84(7):1535-1543. PubMed ID: 29522648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the cystometric filling rate affect the afferent bladder response pattern? A study on single fibre pelvic nerve afferents in the rat urinary bladder.
    De Wachter S; De Laet K; Wyndaele JJ
    Neurourol Urodyn; 2006; 25(2):162-7. PubMed ID: 16372317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder.
    Serra DB; Affrime MB; Bedigian MP; Greig G; Milosavljev S; Skerjanec A; Wang Y
    J Clin Pharmacol; 2005 Sep; 45(9):1038-47. PubMed ID: 16100298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.
    Dwyer P; Kelleher C; Young J; Haab F; Lheritier K; Ariely R; Ebinger U
    Neurourol Urodyn; 2008; 27(6):540-7. PubMed ID: 18663723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists.
    Naito R; Yonetoku Y; Okamoto Y; Toyoshima A; Ikeda K; Takeuchi M
    J Med Chem; 2005 Oct; 48(21):6597-606. PubMed ID: 16220976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Overactive bladder].
    Krankenpfl J; 2005; 43(1-3):60. PubMed ID: 15912847
    [No Abstract]   [Full Text] [Related]  

  • 13. Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder.
    Zinner N
    Expert Opin Pharmacother; 2007 Mar; 8(4):511-23. PubMed ID: 17309345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Overactive bladder: a better understanding of pathophysiology, diagnosis and management. A. J. Wein and R. R. Rackley J Urol, suppl., 2006; 175: S5-S10.
    Löfgren OE
    J Urol; 2007 Oct; 178(4 Pt 1):1553; author reply 1553. PubMed ID: 17707052
    [No Abstract]   [Full Text] [Related]  

  • 15. Differential roles of M2 and M3 muscarinic receptor subtypes in modulation of bladder afferent activity in rats.
    Matsumoto Y; Miyazato M; Furuta A; Torimoto K; Hirao Y; Chancellor MB; Yoshimura N
    Urology; 2010 Apr; 75(4):862-7. PubMed ID: 20156651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inhibitory role of acetylcholine and muscarinic receptors in bladder afferent activity.
    Daly DM; Chess-Williams R; Chapple C; Grundy D
    Eur Urol; 2010 Jul; 58(1):22-8; discussion 31-2. PubMed ID: 20071074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of darifenacin on overactive bladders in female and male rabbits.
    Levin RM; Juan YS; Whitback C; Perez-Martinez FC; Lin WY
    Int Urol Nephrol; 2008; 40(2):303-9. PubMed ID: 17680338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darifenacin: Pharmacology and clinical usage.
    Steers WD
    Urol Clin North Am; 2006 Nov; 33(4):475-82, viii. PubMed ID: 17011383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of DA-8010, a novel muscarinic receptor antagonist selective for urinary bladder over salivary gland.
    Lee MJ; Moon JH; Lee HK; Cho CH; Choi SH; Im WB
    Eur J Pharmacol; 2019 Jan; 843():240-250. PubMed ID: 30502343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinergic activation of phasic activity in the isolated bladder: possible evidence for M3- and M2-dependent components of a motor/sensory system.
    Finney SM; Stewart LH; Gillespie JI
    BJU Int; 2007 Sep; 100(3):668-78. PubMed ID: 17627783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.